Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474104 | 0.85 | L3MBTL1 (0.69) | L3MBTL1MTNR1AMTNR1BAOC3FFAR1 | |
| SCHEMBL29110950 | 0.84 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3FFAR1 | |
| SCHEMBL12191930 | 0.83 | MTNR1A (0.56) | L3MBTL1MTNR1AMTNR1BFFAR1LMNA | |
| SCHEMBL12191931 | 0.83 | MTNR1A (0.56) | L3MBTL1MTNR1AMTNR1BFFAR1LMNA | |
| SCHEMBL27935776 | 0.79 | POLB (0.50) | L3MBTL1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL13814395 | 0.79 | AOC3 (0.51) | L3MBTL1MTNR1AMTNR1BAOC3 | |
| SCHEMBL12174660 | 0.78 | L3MBTL1 (0.62) | L3MBTL1MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL11082143 | 0.77 | L3MBTL1 (0.75) | L3MBTL1MTNR1AMTNR1BAOC3 | |
| SCHEMBL5778033 | 0.76 | AOC3 (0.50) | L3MBTL1MTNR1AMTNR1BAOC3 | |
| SCHEMBL19313159 | 0.76 | MTNR1A (0.49) | L3MBTL1MTNR1AMTNR1BAOC3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253518-A1 | KINASE INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253518-A1 | KINASE INHIBITOR | LATS2, LATS1, MAP3K6 | L3MBTL1 674/4885MTNR1A 4647/4885MTNR1B 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.